Molecule

BTK

B-cell receptor kinase

Expression change
Active
Evidence level
moderate
Targeted by
Ibrutinib

Role in pathogenesis

Downstream of MYD88 in B-cell signalling. Also regulates NLRP3 inflammasome. Ibrutinib (BTK inhibitor) reduces both symptoms AND IgM levels.

Targeting drugs (1)

DrugMechanismResponse rateLine
IbrutinibBTK inhibitorComplete in case reportsAlternative

Sources (1)

I5Huang Y et al. (2022) Ibrutinib for MYD88 L265P-positive SchnitzlerDOI ↗